Unlike traditional drug development, cell therapy logistics require extremely close, integrated relationships with contract research (CRO) and manufacturing (CDMO) organizations. Due to the direct line from patient to manufacturing and back, these partners function as critical extensions of the core team to ensure timeliness and safety.
Instead of harvesting mature macrophages, Resolution Therapeutics extracts their precursor cells (monocytes). This allows them to control differentiation outside the body with a specific cytokine mix, "phenotype locking" the cells into a desired regenerative state before reintroduction into a patient's highly inflamed liver environment.
To de-risk clinical programs from recruitment and activation hurdles within the UK's strained NHS, companies like Resolution Therapeutics run an equal number of trial sites in other countries, like Spain. This geographic diversification provides a valuable real-time benchmark and a hedge against single-country operational delays.
While the UK's world-class universities provide a rich pipeline of scientific talent for biotechs, the country's clinical trial infrastructure is a significant hurdle. Immense pressure on the NHS creates delays in site opening and patient recruitment, creating a fundamental friction point in the biotech value chain.
The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.